Article Figures & Data
Figures
- FIGURE 1.
Biodistribution: Whole-body images of 1 patient at various times after injection of 89Zr-IAB22M2C (1.5-mg minibody dose). All images show most intense activity within spleen, followed by marrow, liver, and kidneys.
- FIGURE 2.
Biodistribution and normal-organ uptake in 6 patients at 2–4 h (A), 24 h (B), and 92–148 h (C) after injection of 89Zr-IAB22M2C (0.2- to 10.0-mg minibody dose).
- FIGURE 3.
Serum (A) and whole-body clearance (B) of 89Zr-IAB22M2C at various mass levels, in aggregate mean values of decay-corrected activity retention. %ID = percentage injected dose; WB = whole body.
- FIGURE 4.
Normal-organ uptake (mean SUVLBM) in spleen (A), marrow (B), liver (C), nodes (D), and muscle (background uptake) (E) vs. minibody mass. BM = bone marrow.
- FIGURE 5.
A 24-h whole-body (maximum-intensity projection) image in patient imaged with 0.2 mg of 89Zr-IAB22M2C. (A) Intense uptake is noted in lymph nodes. (B and C) Fusion image at 24 h shows 89Zr-IAB22M2C uptake in lesion in deltoid (B), which was also 18F-FDG–positive (C). (D) Hematoxylin- and eosin-stained section shows melanoma tumor nodules on right within skeletal muscle. (E) Immunohistochemistry highlights presence of CD8+ T cells at periphery and infiltrating tumor.
- FIGURE 6.
Whole-body (maximum-intensity projection) image (left) and 89Zr-IAB22M2C (0.5 mg) images (right) of patient with hepatocellular carcinoma. 89Zr-IAB22M2C–positive lesions are seen in 2 liver metastases (SUVmax, 14.6 and 22.85), and additional uptake is seen in 3 abdominal lymph node metastases (SUVmax, 5.85–10.9).
- FIGURE 7.
Whole-body (maximum-intensity projection) image (A), 89Zr-IAB22M2C (1.0 mg) images (B), and 18F-FDG images (C) of patient with lung cancer not initiated on immunotherapy. Lesions that are 18F-FDG–positive in left neck (SUVmax, 17.8; 3.2 cm), mediastinum (SUVmax, 11.1; 2.2 cm), left upper lobe (SUVmax, 20.4; 4.7 cm), and liver (SUVmax, 11.6; 3.7 cm) show no uptake of 89Zr-IAB22M2C.
Tables
Demographic Data Total patients (n) 6 Age range (y) 38–81 Sex (n) Male 3 Female 3 Primary malignancy (n) Melanoma 1 Hepatocellular carcinoma 1 Lung 4 Treatment profile for current immunotherapy (n) None 1 Current < 1 mo from imaging 1 Current > 6 mo from imaging 2 Prior > 6 mo from imaging 2
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
- Multiparametric MRI of Early Tumor Response to Immune Checkpoint Blockade in Metastatic Melanoma
- Imaging of T-cell Responses in the Context of Cancer Immunotherapy
- Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET
- Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial
- ICAM-1 orchestrates the abscopal effect of tumor radiotherapy
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
- Quo Vadis, Molecular Imaging?
- Can Molecular Imaging Measure T-cell Activation?
- The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment